Intellia Therapeutics

It is a biotechnology company developing biopharmaceuticals using a CRISPR gene editing system.

NTLA Nasdaq ISIN US45826J1051 SEC CIK 1652130 LEI 5493002T5BCPE5DZC723
Follow Intellia Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $7.2M −48% vs same quarter last year
Net income −$127.5M −25.8% vs same quarter last year
EPS, diluted −$0.91 +1.1% vs same quarter last year
Operating cash flow −$85.4M −11.1% vs same quarter last year
Revenue by quarter
$12.9M
$16.6M
$14.2M
$13.8M
$23M
$15M
$7.7M
$7.2M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income12 fiscal years
  • Revenue
  • Net income
−$600M−$400M−$200M$0$200MFY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$67.7M−$412.7M
FY24$57.9M−$519M
FY23$36.3M−$481.2M
FY22$52.1M−$474.2M
FY21$33.1M−$267.9M
FY20$58M−$134.2M
FY19$43.1M−$474.2M
FY18$30.4M−$85.3M
FY17$26.1M−$67.5M
FY16$16.5M−$31.6M
FY15-−$12.4M
FY14--
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−1500%−1000%−500%0%500%FY15FY17FY19FY21FY23FY25
Show the numbers
YearGross marginOperating marginNet margin
FY25-−651.7%−609.9%
FY24-−923.1%−896.8%
FY23-−1420.5%−1326.5%
FY22-−879%−909.8%
FY21100%−810.4%−810.5%
FY20100%−235.5%−231.5%
FY19100%−246.8%−1100.1%
FY18100%−298.6%−280.4%
FY17-−266.3%−258.6%
FY16-−195.2%−192%
FY15---
FY14---
Free cash flowOperating cash flow minus capital expenditure
−$600M−$400M−$200M$0$200MFY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$395.9M
FY24−$354.7M
FY23−$408.1M
FY22−$346.8M
FY21−$237.8M
FY20−$53.5M
FY19−$110M
FY18−$67.6M
FY17−$75.4M
FY16$29.9M
FY15−$4.3M
FY14-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Intellia Therapeutics
  • Healthcare median
−1500%−1000%−500%0%FY15FY17FY19FY21FY23FY25
Show the numbers
YearIntellia TherapeuticsHealthcare median
FY25−609.9%−30.6%
FY24−896.8%−47%
FY23−1326.5%−58%
FY22−909.8%−80.4%
FY21−810.5%−71.9%
FY20−231.5%−62.2%
FY19−1100.1%−46.3%
FY18−280.4%−49.6%
FY17−258.6%−45.9%
FY16−192%−36%
FY15-−38.4%
FY14-−35.5%